UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 153

Sortiert nach

Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy

The FASEB journal, 2018-03, Vol.32 (3), p.1537-1549

2018

Volltextzugriff (PDF)

miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes

The Prostate, 2011-04, Vol.71 (5), p.538-549

2011

Volltextzugriff (PDF)

The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer

Clinical cancer research, 2017-11, Vol.23 (21), p.6580-6591

2017

Volltextzugriff (PDF)

A Simple Three-Dimensional In Vitro Culture Mimicking the In Vivo-Like Cell Behavior of Bladder Patient-Derived Xenograft Models

Cancers, 2020-05, Vol.12 (5), p.1304

2020

Volltextzugriff (PDF)

Programmable Bispecific Nano-immunoengager That Captures T Cells and Reprograms Tumor Microenvironment

Nano letters, 2022-09, Vol.22 (17), p.6866-6876

2022

Volltextzugriff (PDF)

An Androgen-Regulated miRNA Suppresses Bak1 Expression and Induces Androgen-Independent Growth of Prostate Cancer Cells

Proceedings of the National Academy of Sciences - PNAS, 2007-12, Vol.104 (50), p.19983-19988

2007

Volltextzugriff (PDF)

miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src

Cancer research (Chicago, Ill.), 2015-12, Vol.75 (24), p.5309-5317

2015

Volltextzugriff (PDF)

Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer

PloS one, 2013, Vol.8 (4), p.e61064-e61064

2013

Volltextzugriff (PDF)

Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer

Scientific reports, 2023-06, Vol.13 (1), p.9617-9617, Article 9617

2023

Volltextzugriff (PDF)

COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin

Molecular cancer therapeutics, 2018-02, Vol.17 (2), p.474-483

2018

Volltextzugriff (PDF)

Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells

Scientific reports, 2017-09, Vol.7 (1), p.12277-10, Article 12277

2017

Volltextzugriff (PDF)

Self‐Assembled Nanoparticle‐Mediated Chemophototherapy Reverses the Drug Resistance of Bladder Cancers through Dual AKT/ERK Inhibition

Advanced therapeutics, 2020-08, Vol.3 (8), p.n/a

2020

Volltextzugriff (PDF)

Oncomir miR-125b Suppresses p14ARF to Modulate p53-Dependent and p53-Independent Apoptosis in Prostate Cancer

PloS one, 2013-04, Vol.8 (4), p.e61064

2013

Volltextzugriff (PDF)

CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors

PloS one, 2013-08, Vol.8 (8), p.e70910-e70910

2013

Volltextzugriff (PDF)

Androgen-Induced Recruitment of RNA Polymerase II to a Nuclear Receptor-p160 Coactivator Complex

Proceedings of the National Academy of Sciences - PNAS, 2003-03, Vol.100 (5), p.2226-2230

2003

Volltextzugriff (PDF)

Phototherapy with Cancer-Specific Nanoporphyrin Potentiates Immunotherapy in Bladder Cancer

Clinical cancer research, 2022-11, Vol.28 (21), p.4820-4831

2022

Volltextzugriff (PDF)

Preclinical Models for Bladder Cancer Research

Hematology/oncology clinics of North America, 2021-06, Vol.35 (3), p.613-632

2021

Volltextzugriff (PDF)

Inappropriate activation of the androgen receptor by nonsteroids : Involvement of the src kinase pathway and its therapeutic implications

Cancer research (Chicago, Ill.), 2006-11, Vol.66 (21), p.10449-10459

2006

Volltextzugriff (PDF)

Negative Modulation of Androgen Receptor Transcriptional Activity by Daxx

Molecular and Cellular Biology, 2004-12, Vol.24 (24), p.10529-10541

2004

Volltextzugriff (PDF)

Fidelity of a PDX-CR model for bladder cancer

Biochemical and biophysical research communications, 2019-09, Vol.517 (1), p.49-56

2019

Volltextzugriff (PDF)

Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia

Nanomedicine, 2019-08, Vol.20, p.102004-102004, Article 102004

2019

Volltextzugriff (PDF)

Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer

Cancer Immunology, Immunotherapy, 2020-11, Vol.69 (11), p.2305-2317

2020

Volltextzugriff (PDF)

Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis

Cancer letters, 2021-04, Vol.504, p.49-57

2021

Volltextzugriff (PDF)

Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model

Nanomedicine, 2018-04, Vol.14 (3), p.789-799

2018

Volltextzugriff (PDF)

1 – 25 von 153

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(118)
Mit Volltextzugriff
(143)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy

miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes

The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer

A Simple Three-Dimensional In Vitro Culture Mimicking the In Vivo-Like Cell Behavior of Bladder Patient-Derived Xenograft Models

Programmable Bispecific Nano-immunoengager That Captures T Cells and Reprograms Tumor Microenvironment

An Androgen-Regulated miRNA Suppresses Bak1 Expression and Induces Androgen-Independent Growth of Prostate Cancer Cells

miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src

Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer

Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer

COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin

Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors

Self‐Assembled Nanoparticle‐Mediated Chemophototherapy Reverses the Drug Resistance of Bladder Cancers through Dual AKT/ERK Inhibition

Oncomir miR-125b Suppresses p14ARF to Modulate p53-Dependent and p53-Independent Apoptosis in Prostate Cancer

CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors

Androgen-Induced Recruitment of RNA Polymerase II to a Nuclear Receptor-p160 Coactivator Complex

Phototherapy with Cancer-Specific Nanoporphyrin Potentiates Immunotherapy in Bladder Cancer

Preclinical Models for Bladder Cancer Research

Inappropriate activation of the androgen receptor by nonsteroids : Involvement of the src kinase pathway and its therapeutic implications

Negative Modulation of Androgen Receptor Transcriptional Activity by Daxx

Fidelity of a PDX-CR model for bladder cancer

Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia

Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer

Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis

Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model

Suchergebnisse filtern